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ABSTRACT
Aims: Upon entrance into the blood stream most nanoparticles bind to an array of
proteins forming a “protein corona”. Fibrinogen is the second most abundant blood protein
and has been reported to bind to a variety of nanoparticles including metal oxides,
polymeric nanoparticles and carbon nanotubes.
Study Design: Study the effects of oxidation on the binding interactions between human
serum fibrinogen and magnetic iron (III) oxide nanoparticles.
Place and Duration of Study: Department of Chemistry, College of St. Benedict, 37
South College Avenue, St. Joseph, MN 56374, U.S.A., between June 2011 and May
2012.
Methodology: Spectroscopic techniques (UV-Vis, IR, fluorescence, and circular
dichroism) were used to study the binding interactions of magnetic nanoparticles with
human serum fibrinogen and the effects of protein oxidation on its binding affinity.
Results: Magnetic nanoparticles (MNP) formed stable complex with fibrinogen under
physiological conditions. The binding constants (Ka) were determined as 1.91 (± 0.14)x106 M-1 and 1.06 (± 0.09) x106 M-1 at 300 K and 310 K respectively.  The secondary
structure of the protein was slightly affected by the formation of fibrinogen-MNP complex.
When the protein was oxidized with metal catalyzed oxidation (MCO) system, significant
changes in the protein structure was detected leading to decreased binding affinity for
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MNP.
Conclusion: Metal catalyzed oxidation of fibrinogen significantly affects its binding
interactions with magnetic iron (III) oxide nanoparticles.
Keywords: Magnetic nanoparticles, fibrinogen, reactive oxygen species, oxidative stress.
1. INTRODUCTION
Nanoparticles (1-100 nm) are potentially useful tools in medicine and biology as they are of
comparable size to important biological components (e.g. DNA, proteins, cell membranes)
with which they interact [1]. Over the last two decades, numerous potential applications of
nanoparticles have been reported in biomedical imaging, biosensing, drug delivery, and
electronic devices [2]. Recently, the interaction of nanoparticles with proteins has emerged
as a key area of study [3]. Most nanoparticles, upon contact with biological matrices, are
immediately coated by proteins leading to the formation of a protein corona that largely
defines the biological identity of the particle. This protein-nanoparticle interaction may alter
protein conformation, expose new epitopes on the protein surface or perturb the normal
protein function [4]. Adsorption onto nanoparticles has been found to induce protein
aggregation, misfolding, and deactivation [5]. Because the adsorbed proteins determine the
route of internalization, organ disposition and rate of clearance from bloodstream, the
protein-nanoparticle interactions are important for understanding biodistribution,
biocompatibility and therapeutic efficacy of nanoparticles. Currently, the mechanism of
protein binding to nanoparticles is not well characterized.
Due to their unique magnetic properties, magnetic iron (III) oxide nanoparticles (MNP) have
been used for a wide range of biomedical applications such as targeted delivery of drugs
and genes, contrast-enhancing agent for magnetic resonance imaging (MRI), cell
engineering, tissue repair, and hypothermia [6]. Magnetic nanoparticles have also been
reported for many in vivo applications including acting as a tracer of blood flow and inducing
clotting in arteriovenous malformations [7]. Upon administration of MNP intravenously, they
immediately interact with common human plasma proteins, including human serum albumin,
fibrinogen, apolipoprotein A-1, and immunoglobulin G. Initially abundant proteins dominate
the surface of nanoparticles before they are displaced by less abundant proteins with higher
affinity and slower interaction kinetics. Previous kinetic studies on solid lipid nanoparticles
showed that initial protein binding was dominated by albumin, which was replaced over time
by fibrinogen followed by apolipoproteins [8].
Fibrinogen is an adhesive protein that plays a pivotal role in hemostasis [9]. In response to
blood vessel injury, platelets aggregate along with fibrin clots and adhere to extracellular
matrix components readily exposed at the site of vascular damage [10]. Fibrinogen is the
second most abundant protein in human serum. Studies showed that fibrinogen is the most
easily oxidized protein in human blood [11]. Recently the interactions of fibrinogen with gold
nanoparticles, titanium oxide and polystyrene nanoparticles have been reported [12-14].
Reactive oxygen species (ROS) and free radicals contribute to a state of “oxidative stress”
when the cellular antioxidant systems cannot completely inactivate the ROS (O2-, OH., H2O2,singlet oxygen) arising from excessive production of ROS, loss of antioxidant defenses, or
both. Increases in ROS damage proteins, nucleic acids, membrane lipids, and
carbohydrates and can severely compromise cell health and viability leading to cell death.
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Persistent oxidative stress has been implicated in various pathological conditions involving
cardiovascular disease, cancer, diabetics, ischemia/reperfusion, and neurodegenerative
diseases [15].ROS modification leads to increased levels of oxidized amino acid side chains,
carbonylation and glycation [16]. Proteins are also known to be modified by lipid oxidation
products such as malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) [17]. Oxidative
modifications in albumin, the most abundant plasma protein, have been linked to reduced
binding for Cu2+ ions [18]. Oxidation of fibrinogen results in decreased binding activity to
platelet receptor GpIIb/IIIa and delayed fibrin lysis via plasminogen and tissue plasminogen
activator [19-20].
In this study, human serum fibrinogen (HSF) was taken as a model protein to investigate the
effects of oxidative modifications on its binding interactions with magnetic iron (III) oxide
nanoparticles using spectroscopic methods. This paper reports binding constants, quenching
mechanisms, and conformational changes for fibrinogen-MNP interactions under normal and
oxidative stress conditions.
2. MATERIALS AND METHODS
2.1 Chemicals and Reagents
Phosphate buffered saline (PBS), human serum fibrinogen (50-70%) (HSF), magnetic iron
(III) oxide nanoparticles (~ 10 nm) solution, and L-ascorbic acid sodium salt (99%) were
purchased from Sigma and used as received. Ammonium carbonate and ethanol (absolute)
from Sigma-Aldrich, coomassie Blue G-250 and guanidine hydrochloride from Research
Organics, ethylenediaminetetraacetic acid (EDTA) and trichloroacetic acid from Fisher
Scientific were also used (reagent grade).
2.2 UV-Vis Spectrophotometry
Separate solutions comprised of 0.87 µM HSF, 0.22 µM MNP, and a single solution
containing both 0.87 µM and 0.22 µM HSF and MNP respectively were prepared in 0.01M
PBS buffered to a pH of 7.4. A Cary-50 Bio UV- Visible Spectrometer and a 10 mm path
length quartz cuvette were used to obtain absorbance measurements (200-500 nm). The
expected absorption spectrum of HSF- MNP complex was obtained by mathematically
adding the individual spectrum of HSF and MNP. To assess the stability of HSF-MNP
complex over time, a solution containing 0.018 µM HSF and 0.14 µM MNP was prepared
(0.01M PBS) and absorbance at 280 nm were recorded at five minutes intervals for three
and half hours [21]. A 0.01M PBS solution was used as a blank for all measurements.
2.3 Fluorescence Spectroscopy
All fluorescence quenching studies were performed using an OLIS DM45 spectrofluorimeter
and a 10 mm cuvette. For each titration of HSF (both oxidized and unoxidized) against
MNP,solutions containing the same concentration of HSF along with increasing MNP
concentrations were prepared in 0.01M PBS buffered to a pH of 7.4 . The emission spectra
were recorded between 300 and 390 nm after excitation at 283 nm. This procedure was
performed at temperatures of 300 K and 310 K for the protein samples.
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2.4 Circular Dichroism (CD) Spectroscopy
The CD spectra were obtained using a JASCO-810 spectropolarimeter equipped with a
thermostatically controlled cell holder. The temperature of the samples was controlled at 25
± 0.1 0C. A 1 mm path length cuvette was used for all measurement. The CD spectra were
generated by scanning between 200 and 320 nm with an average of three scans and a band
width of 5 nm. The final spectra were obtained by subtracting the buffer contribution from the
original protein spectra.
2.5 Oxidation of Fibrinogen
HSF was oxidized according to the procedure outlined by Tetik, Sermin, et al [19]. A 0.42 µM
HSF solution was introduced to a Fe3+/ascorbate oxidation system with a final concentration
of 100 µM and incubated at a constant temperature of 37 0C using a water bath. Aliquots
were taken after 0, 4, 8, 12, and 24 hours of incubation and quenched by the addition of the
metal chelating agent EDTA at a final concentration of 1 mM. The oxidized samples were
then dialyzed at 4oC using Spectra/Por MWCO dialysis membranes (MWCO: 12-14 kDa)
and filtered via buchner filtration system.
2.6 Carbonyl and Protein Concentration Determination
Carbonyl concentrations for the control and oxidized samples were determined according to
the procedure outlined by C.L. Hawkins et al. [22]. A control solution was prepared without
the addition of the Fe3+/ascorbate oxidation system in order to determine the effect of
incubation on the protein samples.  The Bradford assay (absorbance at 595nm) was used to
determine the concentration of HSF after the oxidation procedure in order to account for any
protein that was lost during the oxidation process.
2.7 Data Analysis
All experimental parameters were estimated as an average of three individual experiments
and expressed as mean ± standard deviation (n = 3). Where necessary, statistical analyses
were performed using student’s t test.
3. RESULTS AND DISCUSSION
3.1 Fibrinogen-magnetic Nanoparticles Binding Interactions
UV-Vis absorption is a simple and applicable method to explore complex formation [23]. As
shown in Fig. 1a, fibrinogen has two strong absorption bands at 230 nm and 280 nm. The
230 nm band is mainly due to the transition of → *of fibrinogen’s characteristic
polypeptide backbone structure C=O [24]. Fig. 1b represents the absorption spectrum of
MNP only. When MNP were added, the UV-Vis spectrum (Fig. 1d) was discernibly different
from the sum of the absorbance of fibrinogen and MNP (Fig. 1c). The conformational
changes reflected by spectral difference at 230 nm in the UV-Vis spectra might arise from
disturbances of polypeptide’s environment of the fibrinogen [25]. The stability of fibrinogen-
MNP complex was examined by monitoring absorbance at 280 nm over time. No significant
changes in absorbance was detected over the length of study (three and half hours)
suggesting a very stable complex formation (data not shown).
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Fig. 1. UV-Vis absorption spectra of fibrinogen and fibrinogen-MNP complex
(a) A 8.7 x 10-7 M fibrinogen solution only, (b) A 2.2 x 10-7 M MNP solution only, (c) mathematical sum
of the absorption spectra of fibrinogen (a) and MNP (b), and (d) fibrinogen-MNP complex with a
concentration of 8.7 x 10-7 M fibrinogen and 2.2 x 10-7 M MNP. All solutions were made in 0.01 M PBS
buffered to a pH of 7.4.
The binding interactions of fibrinogen and MNP were studied with spectrofluorimetry. A fixed
concentration of fibrinogen in PBS was titrated with increasing concentrations of MNP. The
protein was excited at 283 nm and the fluorescence signal was collected for 300 nm – 400
nm with an emission maximum of 338 nm. As shown in Fig. 2, the fluorescence intensity of
the system decreased progressively with increased MNP concentrations. No obvious
wavelength shift in emission maximum was observed for the MNP concentration range.
Fluorescence results were used to determine the binding constant (Ka) using the equationshown below [26]: = + [ ] (1)
whereKa is the binding constant (the reciprocal of Kd), n is the number of binding sites per
HSF, [Q] the concentration of MNP, and F and Forepresent the fluorescence intensities ofHSF in the presence and absence of MNP respectively. The values of Ka were obtained fromthe antilog of the y-intercept of the double logarithm regression curve log (F0 – F)/F versuslog [Q] (Fig. 3). The binding constants were 1.91 (± 0.14) x 106 M-1 and 1.06 (± 0.09) x 106
M-1 at 300 K and 310 K respectively (n = 3).  The linear correlation coefficients of the plots
were larger than 0.99 indicating that the interactions between protein and MNP agreed well
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with the site binding model in equation 1. Similar binding constants have been reported for
many protein-nanoparticle interactions including fibrinogen. Lacerda et al. studied the
interactions of gold nanoparticles with common human blood proteins and reported the
binding constant of human serum fibrinogen with 10 nm gold particles as 0.65 x 106 M-1 [27].
Yang et al. reported the binding constant of bovine serum albumin with 10 nm iron oxide
nanoparticles as 2.40 x 106 M-1 [28].
Fig. 2. Fluorescence spectra of fibrinogen in the presence and absence of MNP.
Fibrinogen concentration was fixed at 1.0 x 10-6 M. MNP concentrations were (1) 0, (2) 0.4, (3) 0.8, (4)
1.2, (5) 1.6, (6) 2.0, (7) 2.4, (8) 2.8, and (9) 3.2 (x 10-6 M) respectively. The fluorescence spectra were
obtained by exciting at 283 nm.
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Fig. 3. Double-log plot of MNP quenching effect on fibrinogen fluorescence at 300 and
310 K (n = 3).
3.2 Quenching Mechanism Analysis
Fluorescence quenching is the decrease of quantum yield of fluorescence from a
fluorophore induced by a variety of molecular interactions including excited-state reactions,
molecular rearrangements, energy transfer, ground-state complex formation and collisional
quenching [29]. These different quenching processes can be divided into two broad
categories i.e. dynamic quenching and static quenching. Dynamic quenching is caused by
collisions between the quencher and the fluorophore during the lifetime of excited state
whereas static quenching refers to fluorophore-quencher complex formation.  Fluorescence
quenching can be described by the Stern-Volmer equation [30]:= 1 + [ ] = 1 + ⌈ ⌉ (2)
where F0 and F represent the fluorescence intensities in the absence and presence ofquencher respectively, Ksv is the dynamic quenching constant, Kq is the quenching rateconstant, [Q] is the concentration of quencher and τ0 is the average fluorescent life time ofthe molecule without quencher.
Dynamic and static quenching can be distinguished by their different dependences on
temperature. Dynamic quenching is caused by a collision which means that higher
temperatures will result in larger diffusion coefficients. As a result, the quenching constants
(Ksv) are expected to increase with temperature. In contrast, static quenching is dominantwhen increased temperature results in decreased Ksv of the quenching.  The dynamicquenching constants (Ksv) calculated for fibrinogen-MNP complexes at two differenttemperatures 300 and 310 K were 1.60 (± 0.02) x 106 M-1 and 1.02 (± 0.03) x 106 M-1
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respectively (Fig. 4). The dynamic quenching constant decreased by about 38% for 10
degrees increase in temperature. The quenching rate constants, Kq were calculated from theKsv values (the τ0 for the biopolymer is often taken as 10-8 s) [31]. The calculated values of Kqwere 1.56 (± 0.06) x 1014 and 1.12 (±0.04) x 1014 L.mol-1s-1 at 300 K and 310 K respectively.
Fig. 4. Stern-Volmer plots of F0/F vs. concentration of MNP at 300 and 310 K (n = 3).
According to the literature, for dynamic quenching, the maximum collision-quenching rate
constant (Kq) of various quenchers with the biopolymer is 2.0 x 1010 L.mol-1s-1 [32].Considering that the quenching rate constant for fibrinogen-MNP interaction is much greater
than 2.0 x 1010 L.mol-1s-1 and that the Ksv decreased with increased temperature, it can beconcluded that the quenching is initiated probably by static quenching resulting from the
formation of fibrinogen-MNP complexes. Static quenching has also been reported for bovine
serum albumin complexes with Ag(I) and magnetic iron (III) oxide nanoparticles [28,33].
3.3 Conformational Analysis
Circular dichroism (CD) spectroscopy is a quantitative technique to investigate the
conformation of proteins and peptides in aqueous solutions [34]. CD spectroscopy was
performed to investigate any changes in the secondary and tertiary structure of fibrinogen
due to binding with MNP (Fig. 5). The far-UV CD spectrum (205 nm – 250 nm) of fibrinogen
exhibits two negative peaks at 208 nm and 222 nm which reflect the characteristics of α-
helices [35]. The two peaks are attributed to the n→π* transition for the peptide bond of α-
helix. The α-helix contents of free and bound fibrinogen were calculated at 208 nm using the
equation [36]: − ℎ (%) = − [ ][ ] × 100 (3)
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where, MRE208 is the observed mean residue ellipticity (MRE) at 208 nm, 4000 is the MRE ofthe β form and 33000 is the MRE value of pure α-helix at 208 nm.
The α-helix content of free fibrinogen was estimated to be ~31% which is close to the
literature value of 32% to 37% in PBS [37]. The addition of MNP caused a slight reduction of
α-helix content to 29.83% which indicated that MNP bound to the amino acid residues of the
main polypeptide chain of fibrinogen and may have interfered with the hydrogen-bond
networks in the region of contact. No noticeable shift in the ellipticity of fibrinogen in the
near-UV region (250-320 nm) was observed after binding with MNP (data not shown).
These findings are consistent with literature showing mild or no changes in α-helix content of
fibrinogen after binding with nanoparticles [38-39].
Fig. 5. Far-UV CD spectra of fibrinogen in absence (a) and presence (b) of MNP
The concentrations of HSF and MNP were 9.0 x 10-7 M and 6.0 X 10-7 M respectively in 0.01 M PBS
buffer at pH = 7.4. The CD spectra were collected at 25 0C with an average of three scans.
3.4 Effect of Oxidation on Fibrinogen-MNP Interactions
To investigate the effect of oxidative modifications of protein on protein-MNP binding
interactions, fibrinogen was oxidized using a metal-catalyzed oxidation (MCO) system [19].
The oxidation of protein usually results in formation of carbonylated amino acid residues.
Therefore, the formation of such groups was measured as a function of time. Fig. 6 shows a
clearly detectable increase in the amount of fibrinogen-bound carbonyl groups. Formation of
carbonyl groups did not reach plateau after 24 hours but incubation for longer than 24 hours
resulted in the development of turbidity indicating the denaturation of the protein.
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Fig. 6. Carbonyl concentration of oxidized fibrinogen as a function of time
A 0.42 µM HSF solution was incubated with 100 µM metal catalyzed oxidation (MCO) system at 37 0C.
Carbonyl groups were measured as DNPH hydrazine derivatives and expressed as nmol carbonyl / mg
protein (n = 3 ).
Steady state fluorescence measurements were used to determine the binding constant for
oxidized fibrinogen and MNP. The results are summarized in Fig. 7. Oxidation of fibrinogen
caused a significant decrease in binding constants. After 4 hours of oxidation, fibrinogen
showed a 75% loss in binding constant compared to that of unoxidized protein. Further
oxidation of fibrinogen (8, 12, and 24 hours) resulted in insignificant binding. Anraku et al.
studied the effects of oxidative stress on the structure of human serum albumin using a
metal catalyzed oxidation system and concluded that the oxidation process affected the
secondary structure of albumin but did not denature the protein [40]. The conformational
changes of albumin resulted in a more open protein molecule with a higher degree of
exposure of hydrophobic area. Petronio et al. studied the effects of oxidation of bovine
serum albumin by HOCl and HOBr and showed that the α-helix content of BSA reduced from
49.5% to 42.4% after treatment with HOBr [41]. The structural properties of oxidized
fibrinogen were examined by CD spectroscopy. The MCO mediated oxidation caused a
gradual loss of in α-helix (data not shown). The α-helix contents in fibrinogen after 4, 8, 12,
and 24 hours of oxidation were calculated to be 28.60%, 27.20%, 24.52% and 16.24%
respectively. The effect of oxidation on fibrinogen was also monitored by measuring
dityrosine formation. Tyrosine residues are known to form dityrosine under oxidative stress
conditions [42]. The status of tyrosine was examined by fluorescence measurement of
dityrosine (excitation λmax = 320 nm, emission λmax = 410 nm). After 4 hours of oxidation,fibrinogen showed a 20% increase in dityrosine fluorescence compared to the unoxidized
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protein. These findings indicate that MCO mediated oxidation significantly affected the
secondary structure of fibrinogen and led to decreased binding with magnetic nanoparticles.
Fig. 7. Binding constant (Ka) of fibrinogen and MNP as a function of oxidation time(n = 3).
4. CONCLUSION
This study was designed to investigate the nature and magnitude of fibrinogen-MNP binding
interactions and the effects of oxidative modifications of fibrinogen on binding. The results
showed that fibrinogen formed a stable complex with MNP under physiological conditions. In
the process of binding, MNP caused a decrease in the intrinsic fluorescence of fibrinogen
through the static quenching mechanism. Metal catalyzed oxidation of fibrinogen resulted in
significant changes in the structure of the protein and adversely affected its binding affinity
with magnetic nanoparticles. These findings are important because fibrinogen is known as
an adhesive plasma protein that plays a pivotal role in hemostasis and its oxidation by
reactive oxygen species (ROS) could affect the blood coagulation process. However, given
the comparatively high fibrinogen concentration in blood, the effect of physiological ROS on
fibrinogen oxidation could be minimal.
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